5 Key Takeaways

• 1

  The ADAPTABLE trial studied 15,076 patients to compare the effectiveness and safety of 81 mg vs 325 mg aspirin for ASCVD prevention.

• 2

  No significant sex-specific differences were found in outcomes between the two aspirin doses among patients with chronic ASCVD.

• 3

  Female patients had a higher risk of hospitalization for stroke but a lower rate of revascularization compared to male patients.

• 4

  The rate of major bleeding was low, with no significant differences between sexes, although females on 81 mg had a higher bleeding rate.

• 5

  The trial supports aspirin's role in ASCVD management, emphasizing the need for dose adjustments based on individual risk factors.